Tap Consulting, LLC Eli Lilly & CO Transaction History

Tap Consulting, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Jul 26, 2022	SELL	$278.73 - $327.27 $37,349 - $43,854	-134 Reduced 3.22%	4,024 $1.31 Million
Q4 2021 Jan 27, 2022	BUY	$224.85 - $279.04 $30,129 - $37,391	134 Added 3.33%	4,158 $1.15 Million
Q3 2021 Nov 03, 2021	SELL	$221.6 - $272.71 $6,204 - $7,635	-28 Reduced 0.69%	4,024 $930,000
Q2 2021 Aug 06, 2021	SELL	$180.55 - $233.54 $10,110 - $13,078	-56 Reduced 1.36%	4,052 $930,000
Q4 2020 Jan 19, 2021	SELL	$130.46 - $172.63 $41,355 - $54,723	-317 Reduced 7.16%	4,108 $694,000
Q3 2020 Oct 20, 2020	BUY	$146.22 - $169.13 $58,634 - $67,821	401 Added 9.97%	4,425 $655,000
Q4 2019 Jan 27, 2020	SELL	$106.92 - $132.43 $427 - $529	-4 Reduced 0.1%	4,024 $529,000
Q3 2019 Nov 08, 2019	SELL	$106.79 - $116.16 $2,135 - $2,323	-20 Reduced 0.49%	4,028 $450,000
Q1 2019 May 03, 2019	BUY	$111.31 - $131.02 $450,582 - $530,368	4,048 New	4,048 $525,000

4,007

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $756B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Tap Consulting, LLC, based on Form 13F filings with the SEC.

Stay updated on Tap Consulting, LLC with notifications on news.